Profiling the Breast Cancer Proteome - The New Tool of the Future?

Clinical Oncology

Volumn 18, Issue 8, 2006, Pages 581-586

  Grassl, J ^a   Morishita, M ^a   Lewis, P D ^a   Leonard, R C F ^a   Thomas, G ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Breast cancer; prognosis; proteomics

Indexed keywords

ANTIESTROGEN; AROMATASE INHIBITOR; PROTEOME; TAMOXIFEN; TRASTUZUMAB; TUMOR MARKER;

ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER STAGING; CLINICAL TRIAL; GENE MUTATION; GENETIC CODE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ONCOGENE; PAGET NIPPLE DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY; TREATMENT INDICATION; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BREAST NEOPLASMS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HUMANS; MICROARRAY ANALYSIS; PROTEINS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 33748288391     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.08.001     Document Type: Article

References (42)

1. Muller V., Witzel I., Pantel K., et al. Prognostic and predictive impact of soluble epidermal growth factor receptor (sEGFR) protein in the serum of patients treated with chemotherapy for metastatic breast cancer. Anticancer Res 26 (2006) 1479-1487
2. Ward D.G., Suggett N., Cheng Y., et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 94 (2006) 1898-1905
3. Ciocca D.R., and Elledge R. Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13 (2000) 1-10
4. Janssens J.P., Verlinden I., Gungor N., et al. Protein biomarkers for breast cancer prevention. Eur J Cancer Prev 13 (2004) 307-317
5. Wright Jr. G.L. Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann Clin Lab Sci 4 (1974) 281-293
6. Bhattacharya B., Prasad G.L., Valverius E.M., et al. Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res 50 (1990) 2105-2112
7. Franzen B., Linder S., Okuzawa K., et al. Nonenzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14 (1993) 1045-1053
8. Wulfkuhle J.D., Sgroi D.C., Krutzsch H., et al. Proteomics of human breast ductal carcinoma in situ. Cancer Res 62 (2002) 6740-6749
9. Luo Y., Zhang J., Liu Y., et al. Comparative proteome analysis of breast cancer and normal breast. Mol Biotechnol 29 (2005) 233-244
10. Hondermarck H., Vercoutter-Edouart A.S., Revillion F., et al. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1 (2001) 1216-1232
11. Vercoutter-Edouart A.S., Lemoine J., Le Bourhis X., et al. Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 61 (2001) 76-80
12. Adriaenssens E., Lemoine J., El Yazidi-Belkoura I., et al. Growth signaling in breast cancer cells: outcomes and promises of proteomics. Biochem Pharmacol 64 (2002) 797-803
13. Hondermarck H., Dolle L., El Yazidi-Belkoura I., et al. Functional proteomics of breast cancer for signal pathway profiling and target discovery. J Mammary Gland Biol Neoplasia 7 (2002) 395-405
14. Umbricht C.B., Evron E., Gabrielson E., et al. Hypermethylation of 14-3-3 sigma (stratifin) is an early event in breast cancer. Oncogene 20 (2001) 3348-3353
15. Benzinger A., Muster N., Koch H.B., et al. Targeted proteomic analysis of 14-3-3 sigma, a p53 effector commonly silenced in cancer. Mol Cell Proteomics 4 (2005) 785-795
16. Moreira J.M., Ohlsson G., Rank F.E., et al. Down-regulation of the tumor suppressor protein 14-3-3sigma is a sporadic event in cancer of the breast. Mol Cell Proteomics 4 (2005) 555-569
17. Craven R.A., and Banks R.E. Laser capture microdissection and proteomics: possibilities and limitation. Proteomics 1 (2001) 1200-1204
18. Wulfkuhle J.D., McLean K.C., Paweletz C.P., et al. New approaches to proteomic analysis of breast cancer. Proteomics 1 (2001) 1205-1215
19. Zhang D.H., Tai L.K., Wong L.L., et al. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors. Proteomics 5 (2005) 1797-1805
20. Zhang D., Tai L.K., Wong L.L., et al. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol Cell Proteomics 4 (2005) 1686-1696
21. Adam P.J., Boyd R., Tyson K.L., et al. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 278 (2003) 6482-6489
22. Petricoin E.F., and Liotta L.A. Proteomic approaches in cancer risk and response assessment. Trends Mol Med 10 (2004) 59-64
23. Li J., Zhang Z., Rosenzweig J., et al. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48 (2002) 1296-1304
24. Laronga C., Becker S., Watson P., et al. SELDI-TOF serum profiling for prognostic and diagnostic classification of breast cancers. Dis Markers 19 (2003) 229-238
25. Vlahou A., Laronga C., Wilson L., et al. A novel approach toward development of a rapid blood test for breast cancer. Clin Breast Cancer 4 (2003) 203-209
26. Becker S., Cazares L.H., Watson P., et al. Surfaced-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) differentiation of serum protein profiles of BRCA-1 and sporadic breast cancer. Ann Surg Oncol 11 (2004) 907-914
27. Pawlik T.M., Fritsche H., Coombes K.R., et al. Significant differences in nipple aspirate fluid protein expression between healthy women and those with breast cancer demonstrated by time-of-flight mass spectrometry. Breast Cancer Res Treat 89 (2005) 149-157
28. Johann Jr. D.J., McGuigan M.D., Patel A.R., et al. Clinical proteomics and biomarker discovery. Ann N Y Acad Sci 1022 (2004) 295-305
29. Mathelin C., Cromer A., Wendling C., et al. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res Treat 96 (2006) 83-90
30. Villanueva J., Philip J., Chaparro C.A., et al. Correcting common errors in identifying cancer-specific serum peptide signatures. J Proteome Res 4 (2005) 1060-1072
31. van't Veer L.J., Dai H., van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415 6871 (2002) 530-536
32. Paik S., Shak S., Tang G., et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351 (2004) 2817-2826
33. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumour specimens. Nat Med 4 (1998) 844-847
34. Sauter G., and Mirlacher M. Tissue microarrays for predictive molecular pathology. J Clin Pathol 55 (2002) 575-576
35. Gulmann C., Sheehan K.M., Kay E.W., et al. Array-based proteomics: mapping of protein circuitries for diagnostics, prognostics, and therapy guidance in cancer. J Pathol 208 (2006) 595-606
36. Makretsov N.A., Huntsman D.G., Nielsen T.O., et al. Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. Clin Cancer Res 10 (2004) 6143-6151
37. Haab B.B. Methods and applications of antibody microarrays in cancer research. Proteomics 3 (2003) 2116-2122
38. Nielsen U.B., and Geierstanger B.H. Multiplexed sandwich assays in microarray format. J Immunol Methods 290 (2004) 107-120
39. Miller J.C., Zhou H., Kwekel J., et al. Antibody microarray profiling of human prostate cancer sera: antibody screening and identification of potential biomarkers. Proteomics 3 (2003) 56-63
40. Zhou H., Bouwman K., Schotanus M., et al. Two-color, rolling circle amplification on antibody microarrays for sensitive, multiplexed serum-protein measurements. Genome Biol 5 (2004) R28
41. Goldman E.R., Mattoussi H., Anderson G.P., Medintz I.L., and Mauro J.M. Fluoroimmunoassays using antibody-conjugated quantum dots. Methods Mol Biol 303 (2005) 19-34
42. Bradford T.J., Wang X., and Chinnaiyan A.M. Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer. Urol Oncol 24 (2006) 237-242